Bush administration says importation does not equal savings

Share this article:
The Bush administration said Tuesday the establishment of a program to safely import prescription drugs is not likely to save U.S. consumers much money.
The study, conducted by a Department of Health and Human Services task force, stopped short of warning legislators to end their efforts to pass legislation that would allow reimportation of prescription drugs. However, the study did conclude that such a system could negatively impact the development of new drugs and also raised liability concerns for consumers, manufacturers, distributors and pharmacies.
"The public's expectation that most imported drugs are less expensive than American drugs is not generally true," said surgeon general Richard Carmona, the task force chairman. Carmona said lower-cost generic drugs account for most of the prescription drugs consumed in the U.S.
The administration would only consider a drug importation system that would be limited to certain, high-volume brand name drugs from Canada, Health and Human Services secretary Tommy Thomson said. But the report raised concerns about drugs in Canadian pharmacies that have been purchased from other countries, making it difficult to determine their safety. 
The report also stated the way that U.S. consumers currently import drugs from Canada and other places is associated with significant risk since there is no way to determine whether the drugs are legitimate and whether they contain the proper amount of medicine.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...